aap Implantate AG

Aap CFO Marek Hahn ends his Management Board activities at the end of the year; contracts of CEO and COO extended until the end of 2025

Q1/2023: Solid start with slight sales growth (+3 %) and unchanged EBITDA; US and LATAM business grow well into double digits

Consolidation in FY/2022: Small decline in sales with stable cost base and strong improvement in operating cash flow (+23 %) in challenging environment

Aap Implants Inc. awarded agreement with Premier, Inc. for Small Joint Implants – Upper Extremities, Small Joint Implants – Lower Extremities, Podiatry Products and Accessories

Aap Implantate AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Aap Implantate AG: Marek Hahn, Subscription of shares as part of the private placement in connection with a rights issue capital increase

Aap Implantate AG: Rubino di Girolamo, Subscription of shares as part of the private placement in connection with a rights issue capital increase

Aap Implantate AG: Deepblue Holding AG, Subscription of shares as part of the private placement in connection with a rights issue capital increase

Aap Implantate AG: Merval AG, Subscription of shares as part of the private placement in connection with a rights issue capital increase

Aap Implantate AG: Agnieszka Mierzejewska, Subscription of shares as part of the private placement in connection with a rights issue capital increase

Aap Implantate AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Aap receives US-American clearance (FDA) for polyaxial LOQTEQ® VA Elbow system; launch planned for Q4 2023

Result of the capital increase with subscription rights: capital measure fully subscribed; issue of 2.4 million new shares leads to gross issue proceeds of around EUR 3.3 million

Aap Implantate AG: Langner Asset Management GmbH, Granting of 10,000 subscription rights within a capital increase with subsription rights

Aap Implantate AG: Deepblue Holding AG, Granting of 155,925 subscription rights within a capital increase with subsription rights

Aap Implantate AG: Jürgen Krebs, Granting of 272,495 subscription rights within a capital increase with subsription rights

Aap Implantate AG: Merval AG, Granting of 545,704 subscription rights within a capital increase with subsription rights

Aap Implantate AG: Marek Hahn, Granting of 9,564 subscription rights within a capital increase with subsription rights

Good start in 2023 after challenging fiscal year 2022

Aap Implantate AG resolves on capital increase with subscription rights to strengthen its financial base